A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
Intratumoral administration of SAR441000 in combination with cemiplimab was generally well tolerated with antitumor activity in the locoregional disease setting. Anecdotal evidence of pharmacodynamic immunomodulatory effect and distant noninjected lesion antitumor response was observed, without significant effects in patients with advanced solid tumors previously treated with anti-PD-1 therapies.
Authors
- Özlem Türeci (ORCID: https://orcid.org/0000-0002-0623-1497)
- Oliver Edgar Bechter (ORCID: https://orcid.org/0000-0003-0667-3284)
- Jochen Sven Utikal (ORCID: https://orcid.org/0000-0001-5316-0241)
- Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
- Joon Sang Lee (ORCID: https://orcid.org/0000-0003-0838-6166)
- Christoffer Gebhardt (ORCID: https://orcid.org/0000-0001-7090-9584)
- Binfeng Xia
- Rahul Marpadga
- Miguel F. Sanmamed (ORCID: https://orcid.org/0000-0002-7295-6074)
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- Jean‐François Baurain (ORCID: https://orcid.org/0000-0003-4876-4600)
- Sylvie Rottey (ORCID: https://orcid.org/0000-0003-2060-3725)
- Stéphane Champiat (ORCID: https://orcid.org/0000-0002-0741-2118)
- Jean‐Jacques Grob (ORCID: https://orcid.org/0000-0002-0667-153X)
- Jessica Cecile Hassel (ORCID: https://orcid.org/0000-0001-7575-6230)
- Alfonso Berrocal (ORCID: https://orcid.org/0009-0001-7457-7879)
- Uğur Şahin (ORCID: https://orcid.org/0000-0003-0363-1564)
- Carmen Loquai
- Barbara Buday
- Patrick Brueck
- Brant Delafontaine (ORCID: https://orcid.org/0000-0001-5762-2423)
- Brian Gastman (ORCID: https://orcid.org/0000-0003-2691-3409)
- Giovanni Abbadessa (ORCID: https://orcid.org/0009-0007-2823-1870)
- Hong Wang (ORCID: https://orcid.org/0000-0002-8787-715X)
- Yue Yang
- Helen Lee
- Gianfranco Di Genova
- Marye J. Boers‐Sonderen (ORCID: https://orcid.org/0009-0005-9624-9189)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Radboud University Nijmegen (NL)
- Inserm (FR)
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Université Paris Cité (FR)
- Aix-Marseille Université (FR)
- Heidelberg University (DE)
- Universitair Ziekenhuis Leuven (BE)
- Ghent University Hospital (BE)
- University Hospital Heidelberg (DE)
- Radboud University Medical Center (NL)
- AVEO Oncology (United States) (US)
- Institut zur Förderung von Bildung und Integration (DE)
- Sorbonne Paris Cité (FR)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- Sanofi (United States) (US)
- Hospital Clínic de Barcelona (ES)
- Hospital General Universitario De Valencia (ES)
- BioNTech (Germany) (DE)
- Clinica Universidad de Navarra (ES)
- Institut de Neurosciences de la Timone (FR)
- Klinikum Bremen-Mitte (DE)
- University Medical Centre Mannheim (DE)
- Sanofi (Hungary) (HU)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1983
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- Sanofi